Onconase®, our lead investigational drug, has been evaluated in over 850 patients with a variety of solid tumors in Phase I to III studies. Survival benefits have been seen in patients with:
- Malignant Mesothelioma
- Non Small Cell Lung Cancer (NSCLC)
- Advanced Breast Cancer
- Renal Cell Carcinoma
|
